title: The GH/IGF-1 system in critical illness.
abstract: The Growth Hormone and Insulin-like Growth Factor-1 (IGF-1) axis plays a pivotal role in critical illness, with a derangement leading to profound changes in metabolism. Protein wasting with skeletal muscle loss, delayed wound healing, and impaired recovery of organ systems are some of the most feared consequences. The use of human recombinant Growth Hormone (rhGH) and Insulin-like Growth Factor-1 (IGF-1) - alone and in combination - has been studied extensively in preclinical and clinical trials. This article reviews the current knowlegde and clinical practice of the use of rhGh and IGF-1 in critically ill patients, with a special focus on the trauma and burns patient population.
authors.affiliation: Department of Surgery, University of Texas Medical Branch and Shriners Hospitals for Children, 815 Market Street, Galveston, TX 77550, United States.
authors.forename: Itoro E
authors.initials: IE
authors.lastname: Elijah
authors.forename: Ludwik K
authors.initials: LK
authors.lastname: Branski
authors.forename: Celeste C
authors.initials: CC
authors.lastname: Finnerty
authors.forename: David N
authors.initials: DN
authors.lastname: Herndon
mesh_terms: D045930:Anabolic Agents / Q000627:therapeutic use*; D000818:Animals; D002056:Burns / Q000188:drug therapy / Q000628:therapy; D003422:Critical Care / Q000639:trends; D016638:Critical Illness / Q000628:therapy*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects; D014947:Wounds and Injuries / Q000188:drug therapy / Q000628:therapy
chemical_list: D045930:Anabolic Agents; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I